Personal Finance

Here's Why Clementia Pharmaceuticals Rocketed Higher Today

Hand shaking

What happened

Shares of Clementia Pharmaceuticals (NASDAQ: CMTA) are up 74% at 11:55 a.m. EST because the Canadian biotech is being bought by the French drugmaker Ipsen for $25 per share. The deal also includes a contingent value right (CVR) that could garner investors another $6 per share.

So what

With just one drug in clinical development, Clementia looks like a prototypical biotech that was built to eventually be acquired. The company is developing a drug that stimulates the retinoic acid receptor gamma called palovarotene, which it's testing as a treatment for two rare bone disorders called fibrodysplasia ossificans progressiva (FOP) and multiple osteochondromas (MO), as well as other diseases.

In the second half of this year, the company plans to file for FDA approval for the occasional treatment of FOP when it flares up, setting up a potential approval next year. It's also testing the drug for chronic dosing for FOP in a late-stage study.

Further back, palovarotene is in a midstage clinical trial for MO and an early stage study for dry eye disease. It also has a few other molecules in the same class as palovarotene that are in preclinical development.

The aforementioned $6 CVR will be paid out after the FDA accepts the marketing application for palovarotene for the treatment of MO.

Hand shaking

Image source: Getty Images.

Now what

Clementia's shares are trading above $25, suggesting either investors think there's a good chance that palovarotene will work in MO and the CVR will payout or they're hoping that someone will come in and outbid Ipsen. Considering the substantial premium Ipsen is paying, the latter seems unlikely, but certainly not impossible. This is the biotech industry, after all.

10 stocks we like better than Clementia Pharmaceuticals

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Clementia Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of January 31, 2019

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More